

RESEARCH AND DEVELOPMENT

Date request received	12/06/2025	FOI Ref	29167
-----------------------	------------	---------	-------

Details of FOI Request

Q5.	Does you trust participate in any clinical trials for the treatment of renal cell carcinoma? If so, please provide the name of each trial and number of patients that are taking part?
-----	--

RESPONSE

Study Short Title	Study Full Title	Active Participants
LION	Pan Tumour Trial of Cox-Inhibitor and Immune Checkpoint Blockade, LION is a phase II, open label, multicentre trial of the addition of celecoxib to standard of care immune-checkpoint blockade in Triple Negative Breast Cancer (TNBC), Non-Small Cell Lung Cancer (NSCLC) and Renal Cell Carcinoma (RCC) (clear cell and papillary histological subtypes).	1 on follow-up
Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART)	Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART): An international investigator-led phase III multi-arm multi-stage randomised controlled platform trial of adjuvant therapy in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse	12 on follow-up
CA209-9ER: Advanced or Metastatic Renal Cell Carcinoma	A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma	Closed to recruitment No Active Participants

Additional Commentary

Request received by R&D 12/06/2025.

With reference to the clinical trial question (Q5), the data included relates to any clinical trials for the treatment of Renal Cell Carcinoma (RCC) which are currently recruiting participants or have participants under treatment or in follow-up.

The number of active participants relates to those participants currently undergoing treatment or in follow-up.

We have also listed active clinical trials at RCHT that do not have any active participants.

Thankyou.

Date Response Sent

24/06/2025